Autolus TherapeuticsAUTL
Recorded

Autolus Therapeutics 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration37 minParticipants12

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good day, and thank you for standing by. Welcome to Autolus Therapeutics Third Quarter 2026 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference call is being recorded. I would now like to hand the conference over to your first speaker today, Amanda Cray, Executive Director of Investor Relations.

Amanda CrayExecutive Director of Investor Relations

Please go ahead. Thank you, Stephanie.

Amanda CrayExecutive Director of Investor Relations

Good morning or good afternoon, everyone, and thank you for joining us on today's call. With me are Chief Executive Officer, Dr. Christian Itin, and Chief Financial Officer, Rob Dolski. I would like to remind everyone on slide two that during today's call, we will make statements related to our business that are forward-looking under federal securities laws and the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These may include, but are not limited to, statements regarding commercialization and manufacturing of AUCATZYL in the U.S. and U.K., our full year 2026 net product revenue outlook, our anticipated cash runway and financing assumptions, and the therapeutic potential, clinical development, regulatory timelines, and market opportunities for obe-cel and our other product candidates.

Amanda CrayExecutive Director of Investor Relations

These statements are subject to a variety of risks and uncertainties that could cause actual results to differ materially from expectations and reflect our views only as of today. We assume no obligation to update any such forward-looking statements. For a discussion of the material risks and uncertainties that could affect our actual results, please refer to the risks identified in today's press release and in our SEC filings, both available on the Investors section of our website. On slide three, you will see the agenda for today's call. As usual, Christian will provide an overview of our operational highlights, Rob will then discuss the financial results, and Christian will conclude with upcoming milestones and closing remarks. We will then take questions. With that, I will turn it over to Christian.

Christian ItinCEO

Thanks, Amanda, and welcome to our third quarter 2026 update. Moving to slide number 4. We had a strong quarter with $41.2 million in AUCATZYL net revenues, which is 95% up from Q3 in 2025. Looking at the first nine months of 2026, we are at $113.1 million net sales, up by 122% compared to the first nine months in 2025. Center onboarding is progressing ahead of plan, with 90 centers in the U.S. and 18 in the U.K. authorized. The U.K. launch is going well, and we expect to break out U.K. sales with the full-year financials. Critical for this performance are the positive experience of treating physicians with AUCATZYL and the consistently high performance of our teams throughout the year. At ASH, we expect the next update of the real-world experience with AUCATZYL in presentations from ROCCA. Moving to slide number 5.

Christian ItinCEO

We have demonstrated strong execution of our commercial plan for 2026. Net revenue for the full year was initially expected at a range of $120 million-$135 million. With Q2 financials, we raised guidance to $140 million up to $150 million, and we expect now to be at or above $150 million in net revenue for the full year 2026. The second key objective was to achieve a positive gross margin in 2026. We are tracking at 44% for the first nine months and have reached 57% in Q3. The key drivers for the strong manufacturing performance are volume increase and a relentless drive for efficiency at our nucleus manufacturing facility. For 2026, we had set out to activate 80 centers in the U.S. We have achieved 80 centers in Q3 and are now at 90 centers activated, which creates a strong base to operate from in Q4.

Christian ItinCEO

Moving to slide number 6. Our path to profitability is driven by increase in net sales and improving our gross margin. Use of our product is driven by physicians' experience and confidence in AUCATZYL. Increasing the number of prescribing physicians in authorized centers and use of the product across the full range of the label are the key levers for driving adoption and sales. Gross margin development, in turn, is driven by production volume and efficiency initiatives at our manufacturing facility. As an illustration of the magnitude of the efficiency improvement, we can look at the following metric. In 2026, we will manufacture more than double the number of products as in 2025, with a staffing level that is below our staffing level in 2025. Year to date, we're tracking at 44% gross margin. Slide number 7, and moving to our pipeline activities.

Christian ItinCEO

Today, we are presenting a longer-term follow-up data from our phase I CARLYSLE study in severe refractory SLE patients at ACR in Orlando. The poster will be presented later today and shows sustained clinical responses and safety profile with up to 25 months of follow-up. At ASH, we expect additional data presentations for AUCATZYL in adult relapse refractory ALL patients from clinical trial and real-world experiences. We also expect first data for AUTO8 in light-chain amyloidosis. CATULUS in pediatric ALL patients is on track to complete enrollment end of 2026 or early 2027. LUMINA in refractory lupus nephritis patients continues to enroll. With BOBCAT, we have decided to present data with sufficient follow-up to allow for interpretation of clinical outcome. We will present at ECTRIMS 2027 in October and not at ECTRIMS in March. Moving to slide number 8.

Christian ItinCEO

The clinical aim in progressive MS is to stop progression. Specifically, we are looking for stabilization of EDSS scores, with stabilization maintained over time. KOLs at the recent ECTRIMS 2026 meeting in October were very clear that EDSS stabilization with less than 12 months of follow-up has limited correlation with true disease arrest or even reversal. They considered initial reports from CD19 CAR T programs in progressive MS encouraging, but due to the limited follow-up, the field still lacks proof of concept. In their view, minimal follow-up for an initial interpretation of EDSS scores in progressive MS is 12 months, with a preferable observation period of 24 months. With this very consistent KOL feedback, we have decided to present first data from the BOBCAT study at ECTRIMS in October 2027.

Christian ItinCEO

At that point, we will have 12 patients with at least 12 months of follow-up and 12 additional patients with 6-12 months of follow-up. We are on track with BOBCAT and have no delay in the study. With that, I am handing over to Rob for a review of the financials.

Rob DolskiCFO

Rob? Thanks, Christian, and good morning or good afternoon to everyone.

Rob DolskiCFO

I am pleased to review our financial results for the third quarter ended September 30, 2026. I will be referring to slide 10 in the presentation. Our net product revenue for the third quarter of 2026 was $41.2 million, compared with $21.1 million in the third quarter of 2025, representing a quarter-over-quarter growth of 95%. As Christian noted, based on our year-to-date results, we now expect full year 2026 AUCATZYL net product revenue for both the U.S. and U.K. combined to be at or exceed $150 million, which was the upper end of our prior guidance range. Gross margins improved to 57% in the third quarter compared with 55% in the second quarter of 2026, and a negative gross margin in the third quarter of 2025.

Rob DolskiCFO

The year-over-year improvement was primarily driven by lower manufacturing costs per batch, reflecting increased production volumes, ongoing operational efficiency initiatives, as well as lower inventory reserves and write-offs versus the prior year quarter. Our cost of sales decreased to $17.9 million in the third quarter, compared with $28.6 million for the same period in 2025, reflecting the manufacturing and inventory-related items just discussed. Moving on to research and development, those expenses increased to $30.9 million for the three months ending September 30, 2026, compared to $27.9 million in the same period in 2025. This change was primarily due to an increase in clinical manufacturing supply costs driven by the clinical trial activities and partially offset by a decrease in the R&D headcount-related costs.

Rob DolskiCFO

Our selling, general, and administrative expenses of $35.9 million for the third quarter of 2026 remained fairly in line compared with the $36.3 million in the same period in 2025. Loss from operations for the third quarter was $43.5 million. That is compared with $71.6 million for the same period in 2025. Finally, net loss was $55.1 million for the three months ended September 30, 2026, compared with $79.1 million for the same period in 2025. Turning to the balance sheet, cash equivalents, and marketable securities totaled $248.4 million at September 30, 2026, compared with $201.6 million at the end of June in 2026. The increase here was primarily driven by net cash inflows from the credit facility executed with Perceptive Advisors in July, which included the initial $75 million credit facility tranche taken down at the closing.

Rob DolskiCFO

Our cash runway outlook also assumes proceeds of $25 million from the second tranche available to us, bringing the combined first and second tranches to $100 million. Based on our current operating plans, anticipated AUCATZYL net sales, and these financing assumptions, we expect our current and projected cash equivalents, and marketable securities to fund our operations into the second quarter of 2028. I will now hand back to Christian to wrap up our presentation.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day